<DOC>
	<DOCNO>NCT01128621</DOCNO>
	<brief_summary>A study type 2 diabetic subject stable metformin therapy investigate safety , tolerability , pharmacokinetics pharmacodynamics co-administering single multiple oral dos GSK1292263</brief_summary>
	<brief_title>A Study Type 2 Diabetic Subjects Stable Metformin Therapy Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Co-administering Single Multiple Oral Doses GSK1292263</brief_title>
	<detailed_description>This study investigate safety , tolerability , pharmacokinetics pharmacodynamics GSK1292263 co-administered metformin . The study 2 part . Part A determine PK GSK1292263 follow single day dose type 2 diabetes ( T2DM ) subject metformin . Part B investigate effect 14d co-dosing GSK1292263 BID , 50mg BID sitagliptin placebo 48 T2DM subject take metformin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female subject , 18 65 year age , inclusive . Females nonchildbearing potential . Male subject willing employ appropriate contraception . Except note elsewhere , subject significant know medical condition T2DM would affect safety subject objective study . BMI ( body mass index ) within range 21.837.5 kg/m2 . T2DM diagnose American Diabetes Association criteria least 3 month prior screen . Currently stable metformin therapy . Fasting plasma glucose &lt; = 250mg/dL . HbA1c 6.5 11.0 % . Capable give write informed consent , include compliance requirement restriction list consent form . Average QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject right bundle branch block . Subjects leave bundle branch block eligible . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin &lt; =1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Subjects Gilbert 's syndrome allow participate study . Positive Hepatitis B C , HIV . History uncorrected thyroid dysfunction abnormal thyroid function test . History ketoacidosis lactic acidosis . Fasting triglyceride &gt; 450mg/dL . For female hemoglobin &lt; 11.5g/dL , male hemoglobin &lt; 12.5g/dL . Positive drug/alcohol screen . Smoking . If female pregnant positive pregnancy test lactating . Significant renal disease . Significant ECG abnormality . Systolic blood pressure &gt; 150mmHg &lt; 80mmHg diastolic blood pressure &gt; 95mmHg &lt; 60mmHg screening . Previous use insulin treatment within 3 month screen , &gt; 2 week use acute illness last 12 month prior screen , use 1 year associate gestational diabetes mellitus . History : clinically significant symptom gastroparesis ; symptomatic cholelithiasis obstructive inflammatory gallbladder disease within 3 month prior screen ; gastrointestinal disease could affect fat bile acid absorption , pharmacokinetics pharmacodynamics study drug , include inflammatory bowel disease , chronic diarrhea , Crohn 's malabsorption syndrome within past year ; gastrointestinal surgery may affect pharmacokinetics pharmacodynamics study drug ; , chronic acute pancreatitis . History regular alcohol consumption within 6 month . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month . Has participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . Is take prohibited medication . In Parts A B , subject allow washoff unapproved antidiabetic medication order qualify participation study . • Subjects must wash follow medication 7day period prior first dose , must remain medication discharge Day 2 ( Part A ) Day 15 ( Part B ) : statin agent , fat absorption block agent , bile acid sequestrants . Fibrates must wash 14day period prior first dose . • Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . Unwilling abstain : Caffeineor xanthinecontaining product Day 7 D2 ( Part A ) Day 7 Day 15 ( Part B ) ; use illicit drug nicotinecontaining product ; alcohol Day 7 prior dose D2 ( Part A ) Day 7 Day 15 ( Part B ) ; Consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose study medication collection final pharmacokinetic blood sample . History sensitivity study medication , component thereof , history drug allergy , opinion physician responsible , contraindicate participation . This include sensitivity heparin heparininduced thrombocytopenia , heparin use maintain catheter patency . Where participation study would result donation blood excess approximately 500mL within 56 day period . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Glucose</keyword>
	<keyword>Safety</keyword>
	<keyword>Male</keyword>
	<keyword>Female</keyword>
	<keyword>Metformin</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Type II Diabetes</keyword>
</DOC>